Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year Low After Analyst Downgrade

Sionna Therapeutics, Inc. (NASDAQ:SION) shares reached a new 52-week low during mid-day trading on Monday after BTIG Research downgraded the stock from a buy rating to a neutral rating. The stock traded as low as $4.01 and last traded at $4.50, with a volume of 38338161 shares. The stock had previously closed at $51.04.

Other research analysts also recently issued reports about the stock. Raymond James Financial downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a research report on Monday. Citigroup downgraded shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday. Guggenheim reiterated a “neutral” rating on shares of Sionna Therapeutics in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Wednesday, August 5th. Finally, JonesTrading lifted their price target on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Sionna Therapeutics currently has a consensus rating of “Hold” and an average target price of $42.22.

Insiders Place Their Bets

In other Sionna Therapeutics news, Director Peter A. Thompson sold 85,918 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of Sionna Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 403,726 shares of company stock valued at $18,259,354. 5.10% of the stock is owned by company insiders.

Sionna Therapeutics News Summary

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada upgraded Sionna from “underperform” to “sector perform” and assigned a $5.00 price target, while Stifel maintained a “hold” rating with a $7.00 target. These targets remain above the reported $4.50 share price, suggesting some analysts see potential for recovery. Analyst rating actions
• Neutral Sentiment: Wedbush reaffirmed its “neutral” rating with a $5.00 target, and Guggenheim reaffirmed its “neutral” view. The ratings indicate limited near-term conviction despite targets above the current share price. Analyst rating actions
• Negative Sentiment: Sionna reported topline results from two nucleotide binding domain 1 stabilizer programs targeting cystic fibrosis. Unfavorable clinical data led the company to discontinue SION-719, removing a key development program and weakening the investment case for its cystic fibrosis pipeline. Sionna discontinues cystic fibrosis drug
• Negative Sentiment: Multiple firms reduced their ratings following the trial update: BTIG moved from “buy” to “neutral,” Raymond James cut its view from “strong buy” to “market perform,” and Citizens JMP downgraded Sionna from “market outperform” to “market perform.” The coordinated downgrades reinforce investor concern about the clinical setback. Analyst downgrades
• Negative Sentiment: The sharp decline and unusually heavy trading activity also prompted Johnson Fistel to announce an investigation into potential securities-law violations. The investigation does not establish wrongdoing but adds reputational and legal uncertainty. Johnson Fistel investigation

Institutional Investors Weigh In On Sionna Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. State of Wyoming purchased a new position in shares of Sionna Therapeutics during the 2nd quarter worth approximately $35,000. GF Fund Management CO. LTD. purchased a new stake in shares of Sionna Therapeutics in the fourth quarter valued at approximately $36,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Sionna Therapeutics during the second quarter worth $44,000. Russell Investments Group Ltd. purchased a new position in Sionna Therapeutics in the third quarter worth $30,000. Finally, Balyasny Asset Management L.P. purchased a new position in Sionna Therapeutics in the fourth quarter worth $58,000.

Sionna Therapeutics Price Performance

The business has a fifty day simple moving average of $41.62 and a 200 day simple moving average of $40.17.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). Equities research analysts expect that Sionna Therapeutics, Inc. will post -2.63 EPS for the current year.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.